Name

Bevacizumab + IFL

Alternate names

FOLFIRIB

Primary Site

None

Histology

None

Radiation

None

Remarks

None

Drugs for Bevacizumab + IFL

Name

Alternate Names

5-Fluorouracil
5-Fluracil
Adrucil
Efudex
Fluoroplex
Fluracil
Fluril
Oracil
Ro 2-9757
WR-69596

Abbreviations

5-FU
5FU
FU

Category

Chemotherapy

Subcategory

Antimetabolite

NSC Number

019893
19893

Primary Site

Breast- adjuvant setting and advanced disease
colorectal- adjuvant setting and advanced disease
GI malignancies: anal, esophageal, gastric and pancreatic
Head and Neck cancer
Hepatoma
Ovarian cancer
Skin-Basal cell carcinoma (topical application)

Histology

None

Remarks

Fluorinated pyrimidine; antimetabolite. FDA approved uses on basal cell carcinoma, breast cancer, colorectal cancer, gastric cancer, and pancreatic cancer.

Note: Efudex cream be prescribed to treat AIN III. Code this as chemotherapy.

Coding

This drug should be coded

Name

Alternate Names

Avastin
rhuMAB-VEGF

Abbreviations

None

Category

Biologic therapy (BRM, immunotherapy)

Subcategory

Cytostatic agent--antiangiogenesis agent
Recombinant human anti-VEGF.
Vascular endothelial growth factor receptor inhibitor

NSC Number

704865

Primary Site

Breast- see remarks
Fallopian tube
Ovary
Peritoneum
colorectal
kidney
lung
multiple myeloma
Brain

Histology

None

Remarks

JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, this drug is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Avastin as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this drug as chemotherapy.

FDA has formally revoked its approval of this drug to treat breast cancer. Physicians may still prescribe it but insurers may not pay for it.
FDA approved for colorectal cancer.
FDA approved for treatment of persistent, recurrent or metastatic cervical cancer in combination with paclitaxel and cisplatin or paclitaxel and topotecan.
Nov. 2014: FDA approved in combination with paclitaxel, doxorubicin, or topotecan for the treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
In clinical trials Phase II and III for multiple myeloma
December 12, 2016: Avastin received FDA approval to be used either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.

6/15/18: FDA has approved bevacizumab (Avastin) for patients with epitheliĀ¬al ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgiĀ¬cal resection


June 13, 2018: FDA approved bevacizumab (Avastin) for patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by single-agent bevacizumab, for stage III or IV disease after initial surgical resection.

December 6, 2017: FDA has granted full approval for Avastin (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy

Coding

This drug should be coded

Name

Alternate Names

Calcium folinate
Calcium leucovorin
Calcium leucovorin rescue
Citrovorum Factor
Citrovorum factor rescue
Folic acid
Folinic Acid
Lederfoline
Leucosar
Leucovorin Calcium
Leucovorin rescue
Wellcovorin

Abbreviations

C.F.
CF
CL

Category

Ancillary Agent

Subcategory

None

NSC Number

3590
003590

Primary Site

None

Histology

None

Remarks

The pharmacologically active form of folic acid. FDA approved uses as 1st line colorectal carcinoma in combination with 5-FU and to diminish methotrexate toxicity.

Coding

This drug should NOT be coded

Name

Alternate Names

Camptosar
Camptosar Oral
Camptothecin-11
CPT 11
CPT-11
CPT11
U-101440E

Abbreviations

None

Category

Chemotherapy

Subcategory

Topoisomerase inhibitor

NSC Number

616348

Primary Site

Colorectal
head & neck
Non-small cell lung cancer (NSCLC)
pancreatic cancer
Small cell lung cancer (SCLC)

Histology

None

Remarks

Phase I (head & neck) Phase III SCLC pancreatic Topoisomerase I inhibitor. FDA approved use on colorectal cancer. Pharmacia.

Coding

This drug should be coded
Glossary